Zevra Therapeutics Inc. Watch

from 10-Q 20 pages Zevra Therapeutics, Inc. Employment Agreement Rahsaan Thompson Effective as of June 20, 2024 Zevra Therapeutics, Inc. Employment Agreement

from 10-K 22 pages Zevra Therapeutics, Inc. 2023 Employment Inducement Award Plan

from 8-K 29 pages Contingent Value Rights Agreement by and Between Zevra Therapeutics, Inc. and Computershare Trust Company, N.A. and Computershare Inc., Collectively, as Rights Agent Dated as of November 17, 2023

from 8-K 20 pages Zevra Therapeutics, Inc. Executive Employment Agreement

from 8-K 25 pages Voting and Support Agreement

from 8-K 19 pages Registration Rights Agreement

from 8-K 24 pages Note Purchase Agreement

from 10-Q ~5 pages Zevra Therapeutics, Inc. Ninth Amended and Restated Non-Employee Director Compensation Policy Effective: May 3, 2023

from 8-K 2 pages May 13, 2023 Re: Agreement Regarding Employment Terms Dear Christal

from 8-K 10 pages May 6, 2023 Richard Pascoe R*********@*****.com Re: Transition Agreement

from 10-K 39 pages Zevra Therapeutics, Inc. 2023 Employment Inducement Award Plan Adopted by the Board of Directors: January 6, 2023

from 10-K 1 page Kempharm, Inc. Eighth Amended and Restated Non-Employee Director Compensation Policy Effective: February 15, 2023

from 8-K 9 pages Consulting Agreement

from 8-K 13 pages January 4, 2023 (As Modified on January 5, 2023) Travis Mickle Tmickle@kempharm.com Re: Transition Agreement

from 8-K 2 pages Kempharm, Inc. First Amendment to Executive Employment Agreement

from 8-K 17 pages Parent: KemPharm Inc, a Company Incorporated and Registered Under the Laws of the State of Delaware Having Its Principal Executive Office at 1180 Celebration Blvd., Suite 103, Celebration, Florida 34747, USA of Delaware Having Its Principal Executive Office at 1180 Celebration (The “Parent”), as Owner of the Total Share Capital in the Buyer. the Seller and the Buyer Are Collectively Referred to as the “Parties” and/or Each a “Party”. Whereas (I) the Seller Has Agreed to Sell, Assign and Transfer to the Buyer and the Buyer Has Agreed to Purchase, Accept Assignment and Assume From the Seller the Business (As Defined Below), Excluding the Retained Assets, Upon the Terms and Subject to the Conditions Herein Set Forth; (II) the Seller Is a Late-Stage Biopharmaceutical Company Developing Arimoclomol for Niemann-Pick Disease Type C (Npc); (III) Arimoclomol Is an Investigational Drug Candidate That Amplifies the Production of Heat Shock Proteins (Hsps), Which Can Rescue Defective Misfolded Proteins and Improve the Function of Lysosomes; (III) the Buyer Has Been Informed That the Seller Is in Restructuring Pursuant to the Danish Bankruptcy Act (In Danish: “Konkursloven”);

from 10-Q 2 pages Kempharm, Inc. Seventh Amended and Restated Non-Employee Director Compensation Policy Effective: February 1, 2022

from 8-K 23 pages Kempharm, Inc. Executive Employment Agreement

from 10-Q 13 pages Kempharm, Inc. 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: April 29, 2021 Approved by the Stockholders: June 17, 2021

from 10-Q 26 pages Kempharm, Inc. Amended and Restated 2014 Equity Incentive Plan Adopted by the Board of Directors: November 7, 2014 Approved by the Stockholders: April 1, 2015 Original Effective Date: April 15, 2015 Amended by the Board of Directors: April 29, 2021 Approved by the Stockholders: June 17, 2021